Patent details

Basic Information

Publication number:

EP3209655

PCT Application Number:

US2015021417

Type:

European Patent Granted for LU

Legal Status:

In force

Application number:

EP157143520

PCT Publication Number:

WO2016064445

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS

French Title of Invention:

AGENTS THÉRAPEUTIQUES À BASE DE LANCL2

German Title of Invention:

LANTHIONINSYNTHETASE C-ÄHNLICHE 2-BASIERTE THERAPEUTIKA

SPC Number:

Dates

Filing date:

19/03/2015

Grant date:

15/07/2020

EP Publication Date:

30/08/2017

PCT Publication Date:

28/04/2016

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

15/07/2020

EP B1 Publication Date:

15/07/2020

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

Expiration date:

19/03/2035

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

19/01/2024

 

 

Name:

NImmune Biopharma, Inc.

Address:

1013 McBryde Lane, VA 24060, Blacksburg, United States (US)

History of Owners

From:

08/07/2020

To:

19/01/2024

Name:

LANDOS BIOPHARMA, INC.

Address:

1800 Kraft Drive Suite 216, Blacksburg, VA 24060, United States (US)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

01/09/2020

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Inventor

1

Name:

BASSAGANYA-RIERA, Josep

Address:

United States (US)

2

Name:

CARBO BARRIOS, Adria

Address:

United States (US)

3

Name:

GANDOUR, Richard

Address:

United States (US)

4

Name:

HONTECILLAS, Raquel

Address:

United States (US)

5

Name:

COOPER, Julian, D.

Address:

United States (US)

Priority

1

Priority Number:

201462068322 P

Priority Date:

24/10/2014

Priority Country:

United States (US)

2

Priority Number:

201562101164 P

Priority Date:

08/01/2015

Priority Country:

United States (US)

Classification

IPC classification:

A61K 31/341; A61K 31/4184; A61K 31/423; A61K 31/44; A61K 31/4427; A61K 31/497; A61P 31/12; C07D 213/69; C07D 307/60; C07D 401/14; C07D 403/12; C07D 413/12; C07D 413/14;

Publication

Bulletin

Bulletin Heading:

CO

Bulletin edition number:

2024/03

Publication date:

05/02/2024

Description:

Section M : Transfers of property (Art. 53 of the law), change of name and/or address

European Patent Bulletin

Issue number:

202029

Publication date:

15/07/2020

Description:

Grant (B1)

Deed

Change of owner(s)

Change Kind/ Decision Type:

Change of ownership

Deed Number:

RC20240000021A

Date Registered:

19/01/2024

Licence Effective Date:

Licence Expiration Date:

Scope of Licence:

Deed Filer:

PROXIP

Journal Edition Number:

Text:

Country Code:

Updated Licence Number:

Terminated Licence Number:

Added Owner(s)

Name:

NImmune Biopharma, Inc.

Address:

1013 McBryde Lane, VA 24060, Blacksburg, United States (US)

Removed Pledgee

Name:

Address:

Annual Fees

Annual Fee Due Date:

31/03/2026

Annual Fee Number:

12

Annual Fee Amount:

165 Euro

Expected Payer:

Last Annual Fee Payment Date:

26/03/2025

Last Annual Fee Paid Number:

11

Last Annual Fee Paid Amount:

148 Euro

Payer:

ELION IP S.L.

Filing date	Document type	Number of pages
01/09/2020	Power Of Attorney	1
01/09/2020	Outgoing Correspondence	1
19/01/2024	Request For Change	2
23/01/2024	Outgoing Correspondence	1